Capricor Therapeutics
CAPR
18 hedge funds and large institutions have $630K invested in Capricor Therapeutics in 2017 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 6 closing their positions.
0.84% less ownership
Funds ownership: 4.2% → 3.35% (-0.84%)
14% less funds holding
Funds holding: 21 → 18 (-3)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
50% less capital inflows, than outflows
Capital inflows: $403K | Capital outflows: $800K
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Virtu KCG Holdings
New York
|
+$279K |
| 2 |
Coastal Bridge Advisors
Westport,
Connecticut
|
+$73.2K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$32K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$12.3K |
| 5 |
JP Morgan Chase
New York
|
+$3.66K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$390K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$209K |
| 3 |
Bank of New York Mellon
New York
|
-$51K |
| 4 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$44.5K |
| 5 |
Goldman Sachs
New York
|
-$31K |
CAPR Hedge Fund Activity: Q2 2017 in Review
18 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q2 2017, worth a combined $630K — down 79% from $3.01M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of CAPR and 3 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 4 added.
The largest buyer was Virtu KCG Holdings, adding an estimated $279K. The largest seller was Sabby Management, cutting an estimated $390K.
- 18 institutional investors held Capricor Therapeutics (CAPR) as of Q2 2017, down from 21 in Q1 2017.
- Funds reported $630K of Capricor Therapeutics stock for Q2 2017, down 79% quarter-over-quarter.
- 3 funds opened new Capricor Therapeutics positions in Q2 2017 and 6 closed out, a net change of -3 holders.
- The largest Capricor Therapeutics buyer in Q2 2017 was Virtu KCG Holdings, an estimated $279K added.
- The largest Capricor Therapeutics seller in Q2 2017 was Sabby Management, an estimated $390K sold.
Based on aggregated 13F filings for Q2 2017.